May 08, 2008
Eli Lilly announced that the FDA has approved Strattera (atomoxetine HCI) for maintenance treatment of attention-deficit/hyperactivity disorder (ADHD) in children and adolescents. Strattera, a selective norepinephrine reuptake inhibitor, is the first FDA-approved non-stimulant to treat ADHD in children, adolescents and adults.
Trudell Medical International announced FDA approval of Alvesco (ciclesonide) inhalation aerosol in combination with the Aerocount Dose Indicator. Alvesco, a novel inhaled corticosteroid, will be distributed in the US by Sepracor under an agreement with Nycomed based in Europe.